This week's top news includes combating age-related diseases, and the therapeutic potential of targeting guidance receptors
?? Trending news from the industry
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri, MD, PhD details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
At CTx, Rachel’s contributions to pioneering work drugging novel epigenetic targets led to a first-in-class asset in the clinic targeting ER+ breast cancer, including patients refractory to endocrine therapy. Read the full interview here...
Researchers found that relaxing glial spacing by targeting Plexin-B1 has great therapeutic potential for Alzheimer’s disease. Discover more...
Topological defects in mesenchymal stromal cell self-assembly could suggest their potential for cartilage regeneration. Read on here...
Researchers have developed a new, compact EbCas12a variant that can be packaged into an all-in-one AAV system with its crRNA. Discover more...
?? What to watch
This webinar will offer a comprehensive exploration of the current landscape of immunotherapy research. Our esteemed panel will provide detailed insights into recent developments, including both successes and obstacles encountered within the field.
We will examine:
??The evolving methodologies and emerging technologies shaping immunotherapy
??Considering the challenges that researchers face
领英推荐
??Discuss potential future directions for the field, highlighting opportunities for further advancement.
??? What to attend
Over two separate dates in different locations, you will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR.
Event 1: 12 June 2024, in Oxford (OX1 3QU), United Kingdom - Register HERE
Event 2: 14 June 2024, in Accelerator Utrecht, The Netherlands - Register HERE
Network with your peers. Lunch will be provided.?Registration is required as seating is limited.
?? Listen up!
Listen to our brand new episode titled: 'Exploring the wonders of molecular biology'
In this episode, Matthew Nelson and Jacob Rubens explore our understanding of DNA and its implications for health outcomes, and discuss the transition from DNA sequencing to actionable insights in medicine, contrasting genetics-driven drug discovery with traditional methods.
?? What to read
In collaboration with Halo Labs , we've curated a report that highlights the limitations of monoclonal antibodies in targeting tumour antigens and discusses how genetically engineered medicinal products are leveraging T-cell receptors to broaden immune targets for cancer treatment. Additionally, a new study suggests gene therapy may combat ARVC across various disease stages.
Want to know more? Click here to read more.
Sign up for free! ???
Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.
Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.